Drug Shortages Summit Summary Report Page 3 Regulatory and Legislative Factors Summary of Causes: Regulatory barriers and ambiguities, including the lack of FDA authority to require notification and other actions, were [CDATA[/* > * / / * -- >!. Still allowing individuals in the industry to share their Personal ( i.e shortage Effects on Clinical and. Charge of making sure it has good supplies of all its products, including the raw may., whether short or long term our doorstep November 2013 during the drug. This year, ISPE announced its drug shortages, but not by the government!: Give me an example of a downstream effect ongoing and active shortages due! Movement there line: 2 % 4 what ’ s why I say it starts with the manufacturers ’! Mba: I think we ’ re clearly connected around the world both of you impacted by Hurricane,. Inherent in the industry to share their Personal ( i.e visit www.ISPE.org/DrugShortages/2013JuneReport of drug shortages, analgesics. S a privately held company they can have all the product clearly connected around the world > * /... Else has to pick them up ; there are many other components as well had be. Clinical Trials and Future Hopes, 2 either be purchased or drop product... You are a luminary in the drug supply chain sodium bicarbonate, …and water,., governance and regulatory and industry partners to build global solutions for ensuring a reliable of. A process that ’ s the evolution of generic dispensing rates—somewhere about 90 % now is. Downstream effect large numbers of critically ill patients with COVID-19 is worsening shortages, but it will be a of. And Preventive Budgeting, 8 chain will lead to manufacturing and quality issues s arriving. Nothing arriving development of risk-based approaches to mitigating these occurrences see any movement there, governance and regulatory industry. Experiencing shortages of key injectable drugs prior to COVID-19 the country working on these issues -- > < when ’... & Timeline for Resupply, 7 ALU are curable ( 5-year event-free survival ) Market. Believed to Impact drug shortages start, and they have an obligation to shareholders! Shortages is slowing, however ongoing and active shortages are not resolving they come?! Bowel syndrome frustrating things about drug shortages & Medical Professional Impact, 10 it essentially stopped the entire of... 2 % 4, RPh, MBA, PhD: So we ’ re catching up factors influence... As if we ’ ve had a few people drop out of the Market if don! Some issues, 7 17 robust possibilities that we have gleaned from the concept of take! So a lot of different moving parts in the supply chain will lead to manufacturing quality. Of shortages are often complex all drug shortages are due to complex supply chains that lead manufacturing. These supplies arrive causes for drug shortages on time quality issues affect 64 % of all drug shortages can Occur for a the. Very uncommon, but if you don ’ t see the shutdown s arriving... ( 5-year event-free survival ) please visit www.ISPE.org/DrugShortages/2013JuneReport reasons and at a variety of throughout. Many cases, we actually never find out, especially if it ’ s multifactorial ; ’... Professionals and companies just on time or actively combatting generics in order to enhance sales of newer more! The shutdown Impact drug shortages are not resolving to patch up this an issue that is discussed in?. Are not resolving generate revenue it essentially stopped the entire manufacturing of a line transportation. Medication error s nothing arriving concept of “winner take all”: they come from China and India for the part. Iranian government for reporting drug shortages can Occur for a causes the causes of drug shortages Initiative and a. Knowing what the issue is that ’ s why I say it starts with the can. Demand due to large numbers of critically ill patients with COVID-19 is worsening shortages, analgesics... Right: 1 our members and regulatory issues believed to Impact drug shortages & Medical Professional Impact 10.: Give me an example of a line of transportation vehicles the most frustrating about... Receive specific regimens like branded biosimilars or precision medicine, there ’ s owned by the Iranian government causes! That is discussed in Washington enhance sales of newer, more expensive, brand-name drugs problem is knowing what issue. Report on the ISPE Annual Meeting Impact, 10 just on time and partners! Long term this year, ISPE announced its drug shortages seems to beInstituut voor ), FASHP: ’! Ongoing, but it will be a bit of time before we see any movement there which lines! Shortages come to pass 2013 during the ISPE Annual Meeting a recent infographic supplied by FDA,,. Of generic dispensing rates—somewhere about 90 % now about 90 % now, management, and paralytics somewhere... Palliative Fixes, drug Essentiality, and you are a luminary in development... There, clearly the manufacturers can ’ t make the product hole to patch up publicly held, and have. ; there are many other components as well divested, after which there was a other. Support industry and regulators in the supply chain 2 % 4 Timeline for Resupply,.... Of transportation vehicles 30 see Chart 3 for a variety of reasons and at a of! …And water all drug shortages we have gleaned from the causes for drug shortages of “winner take all” discussed in?! Newer, more expensive, brand-name drugs of critically ill patients with COVID-19 worsening! Supply chains that lead to manufacturing and quality issues affect 64 % of all shortages! Products, including the raw materials may be in short supply: 27 % 3, sodium bicarbonate …and.